AdamCastanoMDMS

Nuclear Cardiology, Non-Invasive Cardiology

Cardiologist, Cardiac Amyloid Specialist

Dr. Castano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

New York Presbyterian Hospital (Columbia Campus)Fellowship, Cardiovascular Disease, 2013 - 2017
Columbia University Mailman School of Public HealthMS, Statistics, 2014 - 2016
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2010 - 2013
Columbia University Vagelos College of Physicians and Surgeons2010 - 2013
University of Michigan Medical SchoolClass of 2010
Princeton UniversityBA, Molecular Biology, Spanish Literature, 2001 - 2005

PubMed

109 citations
Diflunisal for ATTR Cardiac Amyloidosis
Adam Castano, Stephen Helmke, Julissa Alvarez, Susan Delisle, Mathew S. Maurer
Congestive Heart Failure. 2012-11-01
159 citations
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs
Adam Castano, Brian M. Drachman, Daniel P. Judge, Mathew S. Maurer
Heart Failure Reviews. 2015-03-01
67 citations
TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis
Hannah Rosenblum, Adam Castano, Julissa Alvarez, Jeff Goldsmith, Stephen Helmke
Circulation. Heart Failure. 2018-04-01

Drug Reduces Hospitalization, Death from Progressive Form of Heart FailureAugust 27th, 2018
Resurrecting Tc 99m PYP: As Cardiac Amyloidosis Therapies Emerge, an Old Test Gains a New PurposeJuly 16th, 2018